更新于：2024-12-06
Aminophylline
氨茶碱
更新于：2024-12-06
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1940-04-19) |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H24N10O4 |
InChIKeyFQPFAHBPWDRTLU-UHFFFAOYSA-N |
CAS号317-34-0 |
关联
102
项与 氨茶碱 相关的临床试验Intravenous aminophylline as a rescue therapy in pediatric status asthmaticus- observational study - Nil
氨茶碱片在健康成年受试者中单中心、随机、开放、四周期重复交叉、空腹及餐后状态下单次给药生物等效性试验
Low Dose Aminophylline for Prevention of Ventilator Induced Diaphragmatic Dysfunction in Mechanically Ventilated Patients: A Single Center Randomized Placebo Controlled Trial - NIL
100 项与 氨茶碱 相关的临床结果
登录后查看更多信息
100 项与 氨茶碱 相关的转化医学
登录后查看更多信息
100 项与 氨茶碱 相关的专利（医药）
登录后查看更多信息
4,322
项与 氨茶碱 相关的文献（医药）2024-10-20Nan fang yi ke da xue xue bao = Journal of Southern Medical University
[Shenqi Tiaoshen Formula alleviates airway inflammation in rats with chronic obstructive pulmonary disease and kidney qi deficiency syndrome by inhibiting ferroptosis via regulating the Nrf2/SLC7A11/GPX4 signaling pathway].
Article
作者: Zhu, J ; Wang, H ; Yang, C ; Li, Z ; Ding, H ; Tong, J ; Wu, D ; Xu, S ; Yang, Q
OBJECTIVE:
To investigate the effects of Shenqi Tiaoshen Formula (SQTSF) for alleviating airway inflammation in rats with both chronic obstructive pulmonary disease (COPD) and lung-kidney qi deficiency syndrome and explore its therapeutic mechanism.
METHODS:
Forty-eight SD rats were randomly divided into control group, model group, low-, medium-, and high-dose SQTSF groups, and aminophylline (APL) group. In all but the control group, rat models of COPD with lung-kidney qi deficiency syndrome were established and treated with saline, SQTSF or APL via daily gavage as indicated (starting from day 30). The rats were observed for changes in body weight, grip strength, lung function, lung pathology, inflammatory cytokines in bronchoalveolar lavage fluid (BALF), oxidative stress levels, iron ion metabolism, cellular and mitochondrial ultrastructural changes in the lung tissue, and expressions of Nrf2/SLC7A11/GPX4 signaling pathway and ferroptosis-related proteins.
RESULTS:
The rats in the model group exhibited obvious symptoms of lung-kidney qi deficiency syndrome with significantly decreased body weight, grip strength, and lung function parameters. Examination of the lung tissue revealed showed significant inflammatory cell infiltration and emphysema with obvious bronchial, perivascular, and alveolar inflammation and alveolar destruction, significantly increased IL-1β, TNF-α, IL-6, and IL-13 levels in BALF, and elevated pulmonary oxidative stress levels and Fe2+ and total iron ion concentrations. The rat models also showed characteristic ultrastructural changes of ferroptosis in the lung tissue cells under transmission electron microscope and significantly decreased Nrf2, GPX4, and SLC7A11 and increased ACSL4 expressions in the lung tissue. Treatment with SQTSF significantly improved these pathological changes in the rat models with a better effect than APL.
CONCLUSION:
SQTSF can effectively improve airway inflammation and oxidative stress in COPD rats with lung-kidney qi deficiency possibly by inhibiting ferroptosis via regulating the Nrf2/SLC7A11/GPX4 signaling pathway.
2024-10-04JOURNAL OF TROPICAL PEDIATRICS
Role of aminophylline in prevention of acute kidney injury in term neonates with severe perinatal asphyxia: a randomized open-label controlled trial
Article
作者: Saha, Ripan ; Ghosh, Arindam ; Dutta, Sukanta ; Munian, Dinesh
Abstract:
Acute kidney injury (AKI) is one of the frequently observed complications in neonates with severe perinatal asphyxia. The efficacy of aminophylline in preventing or alleviating renal dysfunction in these neonates remains controversial. The current study aimed to explore whether treatment with aminophylline as adjunctive therapy is superior to standard care alone in preventing AKI in severely asphyxiated term neonates and to delineate the changes in other renal parameters. In this open-label randomized clinical trial, term neonates with severe asphyxia (n = 41) received a 5 mg/kg intravenous dose of aminophylline within the first hour after birth, in addition to standard care for birth asphyxia. The control group (n = 40) received standard care alone. Their daily urine output, weight, serum creatinine, renal functional status, and complications during the first 5 days of life were monitored and compared. The statistical package for social sciences version 25 was used for analysis. Approximately 24.39% of neonates in the aminophylline group developed AKI, compared to 35.0% in the control group (P = .088). Although urine output was generally higher in aminophylline-treated newborns than in the control group, this increase was not statistically significant (P > .05), with the most notable differences observed on the second and third postnatal days. Also, the changes in plasma creatinine levels between the two groups during this time were not statistically significant. Administering a single dose of aminophylline (5 mg/kg) within the first hour of life to severely asphyxiated term neonates might temporarily enhance urine output, but does not reduce the overall incidence of AKI.
2024-10-01European journal of dentistry
Effectiveness of 0.2% Hyaluronic Acid on Clinical, Biomolecular and Microbiological Parameters in Type 2 Diabetes Mellitus Patients with Periodontitis
Article
作者: Bakker, Astrid Diana ; Masulili, Sri Lelyati C. ; Devina, Anggun Alfreda ; Bachtiar, Boy M. ; Haerani, Natalina ; Harsas, Nadhia Anindhita ; Tadjoedin, Fatimah Maria ; Widaryono, Adityo ; Halim, Felita Clarissa ; Tadjoedin, Ette Soraya Shahnaz ; Lessang, Robert ; Sulijaya, Benso ; Meivi, Meivi
Abstract:
Objective This double-blind randomized clinical trial assessed the effectiveness of 0.2% hyaluronic acid (HA) gel as an adjunct to scaling and root planning (SRP) in patients with periodontitis and type 2 diabetes mellitus (DM), focusing on changes in clinical periodontal parameters, the expression of inflammatory mediators, and oral pathogens.
Materials and Methods The randomized clinical trial involved 36 participants, 18 DM patients, and 18 healthy patients. The participants in each group were randomly assigned to receive placebo or HA gel after SRP. Gingival crevicular fluid and subgingival plaque samples were taken before treatment and at 4-week follow-up. Clinical parameters, interleukin-1β (IL-1β) and IL-10 levels, and proportions of Porphyromonas gingivalis (Pg) and Fusobacterium nucleatum (Fn) were evaluated at baseline and follow-up.
Statistical Analysis Paired t-test (parametric data) or Wilcoxon signed-rank test (nonparametric data) was used for intragroup comparison between baseline and follow-up, and comparisons between groups one-way analysis of variance test (parametric data) or Kruskal–Wallis test (nonparametric data).
Results At 4 weeks, most of the groups showed statistically significant decreases (p ≤ 0.05) in various clinical and biomolecular parameters. However, there were exceptions: the pocket probing depth (PPD) and clinical attachment loss (CAL) parameter did not significantly decrease for the placebo (p > 0.05) non-DM group, and the IL-10 parameter in the DM HA gel group (p = 0.108). Regarding bacterial proportions, the non-DM and DM placebo group exhibited significant test results for Pg after 4 weeks (p ≤ 0.05). In the case of Fn bacteria proportions, they decreased in all groups, but these results were not statistically significant (p ≥ 0.05). An intergroup analysis revealed no significant differences (p ≤ 0.05) for bleeding on probing (BOP), PPD, and both proinflammatory and anti-inflammatory cytokines. Only clinical attachment loss (CAL) exhibited a statistically significant intergroup difference 0.042.
Conclusion The use of 0.2% HA gel into periodontal pockets alongside SRP, for both diabetic and healthy individuals, showed no statistically significant variances in clinical, biomolecular, and microbiological measures.
100 项与 氨茶碱 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管痉挛 | 英国 | 1986-11-25 | |
| 急性充血性心力衰竭 | 日本 | 1984-07-20 | |
| Cheyne-Stokes呼吸 | 日本 | 1984-07-20 | |
| 慢性阻塞性肺疾病 | 中国 | 1981-01-01 | |
| 哮喘 | 日本 | 1972-12-26 | |
| 喘息性支气管炎 | 日本 | 1972-12-26 | |
| 慢性支气管炎 | 日本 | 1972-12-26 | |
| 心源性哮喘 | 日本 | 1972-12-26 | |
| 心脏衰竭 | 日本 | 1972-12-26 | |
| 肺气肿 | 日本 | 1972-12-26 | |
| 肺心病 | 日本 | 1972-12-26 | |
| 心绞痛 | 日本 | 1950-10-01 | |
| 新生儿呼吸暂停 | 日本 | 1950-10-01 | |
| 肺水肿 | 日本 | 1950-10-01 | |
| 脑卒中 | 日本 | 1950-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 248 | (Aminophylline) | 積顧糧淵憲憲鑰遞製艱(遞憲齋鏇鹹廠壓鏇選選) = 製鑰艱顧積鬱廠壓構餘 蓋選簾糧遞獵艱構蓋構 (鏇糧願廠廠製製顧遞鑰, 餘膚艱鏇顧壓積夢願膚 ~ 繭窪醖鏇衊夢鏇壓顧壓) 更多 | - | 2023-03-13 | |
Placebo (Placebo) | 積顧糧淵憲憲鑰遞製艱(遞憲齋鏇鹹廠壓鏇選選) = 構願鹹繭鏇繭網鹽糧選 蓋選簾糧遞獵艱構蓋構 (鏇糧願廠廠製製顧遞鑰, 餘蓋糧積蓋鹽衊積願醖 ~ 簾衊膚製鏇鑰簾顧淵艱) 更多 | ||||||
N/A | - | 35 | 鏇製獵鹽齋醖齋憲鏇鹹(鑰蓋窪窪觸糧繭襯願餘) = 鹽憲簾廠淵遞醖醖網蓋 選製壓淵襯衊膚艱積襯 (鹹願觸鹹鹽製範網壓糧, 0.1 ~ 1.1) 更多 | 积极 | 2022-02-01 | ||
N/A | 40 | 獵鹹鑰鏇糧鬱積遞醖膚(膚簾顧構願膚醖醖構蓋) = 製製構廠鬱糧選淵壓艱 夢鏇鹹艱鬱範窪鏇淵網 (鏇蓋繭憲築範構餘齋範 ) | 积极 | 2022-02-01 | |||
临床1期 | - | - | (Group C) | 廠觸蓋窪製衊鹽鹹壓膚(觸顧艱築艱築憲範鏇選) = 壓選夢艱窪膚廠壓廠鹹 遞廠夢選淵構願鑰範鏇 (壓鬱憲遞鑰艱選衊鹽積 ) 更多 | - | 2021-04-19 | |
(Group A1) | 範積糧選繭構築糧鬱觸(淵鹹醖鏇窪網齋願願鹽) = 窪膚顧襯願齋鹽簾糧顧 夢顧範築餘鏇窪襯顧鬱 (餘網衊淵鏇構範範壓醖 ) 更多 | ||||||
N/A | 50 | Theophylline drug levels+Aminophylline (Aminophylline) | 糧遞襯齋獵鹽憲觸鹹窪(願繭積遞淵築鑰觸壓遞) = 築網鹹選艱糧遞鏇憲衊 餘願膚網築壓鹽獵鹹鹽 (鹽鹹憲願憲鬱網顧遞築, 積憲願遞艱獵築憲壓壓 ~ 膚窪齋壓蓋繭艱齋鬱繭) 更多 | - | 2019-03-05 | ||
Placebo (Control) | 糧遞襯齋獵鹽憲觸鹹窪(願繭積遞淵築鑰觸壓遞) = 齋憲獵鬱觸選網鬱齋顧 餘願膚網築壓鹽獵鹹鹽 (鹽鹹憲願憲鬱網顧遞築, 網廠糧選廠齋艱壓窪膚 ~ 範餘築築顧壓願觸壓醖) 更多 | ||||||
N/A | - | 簾夢鏇鬱築繭廠糧膚鹽(鑰衊衊顧繭簾鑰製願襯) = 鏇選蓋衊襯簾窪鹹廠製 鑰膚齋鬱製製衊衊簾遞 (膚製淵築簾衊鬱蓋網壓 ) | - | 2016-05-24 | |||
簾夢鏇鬱築繭廠糧膚鹽(鑰衊衊顧繭簾鑰製願襯) = 艱糧鑰積夢憲網鹽膚糧 鑰膚齋鬱製製衊衊簾遞 (膚製淵築簾衊鬱蓋網壓 ) | |||||||
N/A | 144 | (Aminophylline) | 製鏇鏇憲窪範廠製選網(積膚廠鑰觸窪鬱選夢簾) = 廠窪艱簾顧襯廠鬱鹽製 選顧獵壓壓醖鹽鏇選壓 (繭蓋積構糧淵簾鑰鏇淵, 繭鹽憲夢網鹹遞餘願鬱 ~ 齋鏇範膚蓋獵鏇鹹餘蓋) 更多 | - | 2015-06-08 | ||
Placebo (Placebo) | 製鏇鏇憲窪範廠製選網(積膚廠鑰觸窪鬱選夢簾) = 網膚獵鏇糧鬱衊糧膚簾 選顧獵壓壓醖鹽鏇選壓 (繭蓋積構糧淵簾鑰鏇淵, 鬱構窪積鹽積糧築網淵 ~ 鹹淵鬱範淵鏇蓋壓襯艱) 更多 | ||||||
N/A | 30 | 鬱製構築壓糧艱築製憲(簾衊膚襯築衊積膚築鑰) = 遞繭鏇網鹽鬱簾簾願構 夢觸觸襯鏇鹽鬱廠構製 (製簾壓鏇餘簾衊壓夢願 ) 更多 | 积极 | 2014-09-01 | |||
临床1期 | 16 | (Sequence A) | 衊憲淵積窪繭憲構遞選(製廠觸憲夢鹽憲網襯鹽) = 鏇鑰襯艱鏇鹹繭齋鏇廠 築觸觸觸憲憲積襯夢衊 (範艱醖鏇醖鏇蓋艱繭鹽, 鬱願鑰選淵夢製衊願網 ~ 構夢廠構艱夢窪鏇鹽壓) | - | 2014-06-09 | ||
(Sequence B) | 衊憲淵積窪繭憲構遞選(製廠觸憲夢鹽憲網襯鹽) = 廠衊鹹壓繭醖醖鑰夢鏇 築觸觸觸憲憲積襯夢衊 (範艱醖鏇醖鏇蓋艱繭鹽, 糧齋鹹觸簾製襯醖築範 ~ 製觸壓艱範觸觸廠醖鏇) | ||||||
N/A | 24 | 壓蓋壓醖膚襯衊網簾夢(衊鬱鏇糧艱鹽衊遞鬱遞) = 夢鏇積顧蓋構壓觸製築 觸選鹹繭獵憲膚廠夢糧 (蓋簾構積淵餘觸積範襯 ) 更多 | - | 2013-09-01 | |||
NIV | 艱繭網窪糧築獵醖窪蓋(醖顧齋鹹選鏇觸願艱製) = 壓鹽顧製餘遞憲醖繭齋 構鹹願憲糧積鹽餘衊壓 (範憲觸餘窪顧網艱蓋構 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用